SCHEMBL9949779

SCHEMBL9949779

CC(C(=O)N1CC(O)C1)c1ccc(-c2cnn3c(-c4cccc(NC(=O)NCC(F)(F)F)c4)cnc3c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 17/20 0.60
KDR P35968 12/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9951837 0.94 FGFR3 (0.59) FGFR3KDR
SCHEMBL9958343 0.94 FGFR3 (0.59) FGFR3KDR
SCHEMBL15969796 0.93 FGFR3 (0.60) FGFR3KDR
SCHEMBL9950046 0.93 FGFR3 (0.61) FGFR3KDR
SCHEMBL9949676 0.89 FGFR3 (0.62) FGFR3KDR
SCHEMBL9949498 0.89 FGFR3 (0.61) FGFR3KDR
SCHEMBL9949652 0.88 FGFR3 (0.57) FGFR3KDR
SCHEMBL9949662 0.87 FGFR3 (0.61) FGFR3KDR
SCHEMBL9950233 0.86 FGFR3 (0.60) FGFR3KDR
SCHEMBL9950107 0.85 FGFR3 (0.63) FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2017-06-15 US claimed
US-9533954-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2017-01-03 US claimed
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2014-08-28 US claimed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US claimed
WO-2012088266-A2 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2012-06-28 WO claimed
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2020-10-27 US disclosed
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2020-10-27 US disclosed
US-20190240220-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2019-08-08 US disclosed
US-20190240220-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2019-08-08 US disclosed
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2017-06-15 US disclosed
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2017-06-15 US disclosed
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2017-06-15 US disclosed
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2014-08-28 US disclosed
US-8754114-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2014-06-17 US disclosed
US-8754114-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2014-06-17 US disclosed
US-8754114-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2014-06-17 US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US disclosed
WO-2012088266-A2 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190240220-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 FGFR3 1/4885KDR 133/4885
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 FGFR3 1/4885KDR 133/4885
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 FGFR3, FGFR4, FGFR2 FGFR3 1/4885KDR 133/4885
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 FGFR3 1/4885KDR 133/4885
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 FGFR3 1/4885KDR 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.